Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa

Abstract

ObjectivePlasma thrombin generation (TG) provides important information on coagulation status; however, current TG output parameters do not predict major bleeding of patients on anticoagulants. We recently reported that factor V (FV) activation by factor X (FX)a contributes importantly to the initiation phase of TG. Here we investigated how this pathway varies in the normal population and whether FXa‐mediated activation of FV is associated with major bleeding in patients on anticoagulant therapy. ApproachWe employed TIX‐5, a specific inhibitor of FV activation by FXa, to estimate the contribution of FXa‐mediated FV activation to tissue factor (TF)–initiated TG. ResultsWe show that the contribution of this pathway to plasma TG varies considerably in the normal population, as measured by the time needed to form the first traces of thrombin (TG lag time; mean prolongation by TIX‐5 40%, range 0%–116%). Comparing patients on vitamin K antagonists (VKA) of the BLEED study (263 patients with and 538 patients without major bleeding), showed a marked prolongation in the median TG lag time in the presence of TIX‐5 in cases (12.83 versus 11.00 minutes, P = 0.0030), while the TG lag time without TIX‐5 only showed a minor although significant difference (5.83 vs. 5.67 minutes, P = 0.0198). The TIX‐5 sensitivity (lag time + TIX‐5/lag time + vehicle) in the upper quartile was associated with a 1.62‐fold (95% confidence interval 1.04–2.52) increased risk of major bleeding compared to the lowest quartile. ConclusionA greater dependence on FXa‐mediated activation of FV of TG is associated with increased risk of major bleeding during VKA therapy.